Emerging Company Profile: Fatty liver disease has been a hot development area that keeps getting more attention, and one Chinese startup backed by the world’s largest heparin manufacturer is looking to launch a new therapy globally.
April 24, 2019
Learn More
Jeffrey Dao, Operations & Business Development Officer to present HighTide’s HTD1801 for primary sclerosing cholangitis (PSC) at the World Orphan Drug Congress USA 2019 in Oxon Hill, MD...
April 04, 2019
Learn More
[Rockville, Maryland, Dec. 11, 2018] — HighTide Therapeutics, today announced that it will present at Biotech Showcase™ 2019, to be held January 7–9.
December 11, 2018
Learn More
[Rockville, Maryland, Nov. 27, 2018] — HighTide Therapeutics Inc., a clinical-stage biopharmaceutical company, announced that the U.S. FDA has granted Fast Track Designation to its investigational new drug, HTD1801...
November 27, 2018
Learn More
[Rockville, Maryland, October 3, 2018] — HighTide Therapeutics Inc., a clinical-stage biopharmaceutical company participated in the 2nd Annual Pediatric Autoimmune Liver Disease Symposium and...
October 03, 2018
Learn More
HighTide Therapeutics Inc., a globally focused clinical-stage biopharmaceutical company, announced that the U.S. FDA has granted Fast Track Designation to its investigational new drug, HTD1801, for the treatment of patients with primary sclerosing cholang
September 27, 2018
Learn More
© 2023 HighTide Therapeutics, Inc.